Background This review aimed to address what was known about the public health burden associated with novel psychoactive substances (NPS) use, and the effectiveness of responses targeting NPS use and/or associated problems.
Background
Novel psychoactive substances (NPS) are defined as psychoactive drugs not prohibited by the United Nations conventions on drugs. 1 This definition constitutes a diverse category of drug classes (e.g. synthetic cannabinoids, synthetic cathinones, phenethylamines).
2,3 Most NPS are the result of minor changes to molecular structure of well-known legal or illegal drugs (such as cannabis, opioids, ecstasy).
There is debate on the scale of challenges posed by NPS. For example, general population surveys suggest the prevalence of NPS use is relatively low. 4 However, the speed of technological innovation and ease of synthesizing NPS present substantial challenges to regulatory authorities. 2, 3, 5, 6 For example, in 2014, 101 newly identified NPS were reported to the EU early warning system (EWS). 5 The rapidly evolving nature of NPS makes it difficult to assess both current and future harms associated with their use. There are also substantial innovations in global marketing and supply of NPS through the internet that provides a potential platform for growth in NPS use.
Uncertainties associated with the current and future public health burden of NPS suggest the importance of synthesizing available data to inform national and international responses, including for research agenda setting. There is need to estimate the scale of the problem and potential health inequalities; for example, if use is more common in particular subgroups, or if subgroups experience greater harms due to NPS use. Secondly, it is currently unclear what is known about the problems (any acute or chronic healthspecific, social or wider harm due to NPS use, experienced by the user or others) associated with NPS, including risks associated with particular substances, in order to inform interventions. Thirdly, there are issues to do with the availability of interventions for NPS users (including whether some subgroups have lower levels of access to, or engagement in, treatment than other users with problems) and whether there are intervention effectiveness data. Current guidance (e.g. Novel Psychoactive Treatment UK Network (NEPTUNE) 7 ) recommends the adaptation of generic psychosocial interventions for illegal drugs, and therefore we were interested in whether subsequent studies have investigated the effectiveness of these interventions in NPS users. Given the high number of newly identified substances by EWS in the UK and the EU, and uncertainties regarding the current and future public health burden of NPS in the UK, we were commissioned to conduct a review to address these challenges and to identify research priorities for NPS in the UK.
Objectives
The study objectives were to:
• Conduct a scoping review of the international literature on NPS use, related health and social harms (any acute or chronic health-specific, social or wider harm due to NPS use, experienced by the user or others) and public health responses (any intervention at policy, health or other service, or clinical levels, aimed at addressing NPS use and/ or related problems).
• Identify key gaps and more developed areas of the NPS literature, judged most relevant to UK public health research, which may benefit from further exploration through narrative synthesis.
• Conduct narrative syntheses of selected areas of the NPS literature.
To inform these objectives we developed the following research questions a priori to identify key gaps and literature that warranted further narrative synthesis:
• What are the prevalence and patterns of NPS use in the UK general population and do they differ in particular subgroups of the population? 
Methods

Scoping review work
Briefly, we outline below the methods used in our review (for further details, see Appendix 1 and also Mdege et al. 8 ). Literature search strategies are summarized in Box 1.
above, discrepancies resolved through discussion with third author (J.M.).
Data extraction
The data extraction form was designed and piloted by two authors (N.M. and N.D.M.). The following data were extracted:
• General characteristics: location, setting, study design, publication type. Data from each article were extracted by one author and checked by another, with discrepancies resolved by a third author. Authors were contacted for missing or unclear data.
Risk of bias (quality) assessment
No risk of bias assessment was conducted, for further discussion of this decision see Evidence mapping and narrative synthesis.
Evidence mapping and narrative synthesis
We conducted a scoping review of all relevant material to map the available evidence (see Appendix 1 for further details). The extracted data was utilized by one researcher to map the literature according to principal focus (use, problems/harms or responses), NPS type, study design, region, setting, year of publication and publication type. This was checked by another researcher.
We used these data to conduct an evidence gap analysis based on our a priori research questions (see above). The literature was judged to be at an early stage of development such that the benefits of conducting detailed risk of bias assessments were not justified. Selected areas were pragmatically judged to be most promising in terms of having sufficient data to synthesize and likely value in informing thinking about the development of UK public health research priorities.
Results
A total of 13 772 records were identified through electronic databases searches. A further 3260 were obtained through other sources including contacting key researchers and policy experts (Appendix 3). Results are summarized according to three stages of the review: initial evidence mapping of all studies (i.e. scoping review), gap-analysis and narrative synthesis of selected areas of the literature.
Scoping review
General characteristics of the 995 included articles are briefly summarized (Appendix 4). Majority of articles reported on problems. Synthetic cannabinoids and synthetic cathinones were most reported on. Most studies were conducted in general hospital settings, followed by specialist settings. Within hospital settings, most articles were in emergency departments (236 reports), whilst for specialist settings most articles were in poison centres (65 reports). Overall, 252 of the included reports were not specific to a particular setting. most likely explained by a time lag between date of publication and date added to bibliographic databases. We further investigated whether the increase in publications on NPS from 2009 onwards was a general trend or limited to a particular issue within the NPS literature, and found publications across the literature as a whole.
Year of publication
Geographical location
The largest number of studies were conducted in Europe (n = 385), followed by North America (n = 294) and Australia/New Zealand (n = 58). Within Europe, the largest number were conducted in the UK (n = 185). However, it should be noted the grey literature search particularly reflected UK data sources therefore UK research may have been over-represented. In addition searches were limited to English language only.
Study design and principal focus
Most common study designs were case reports/case series (n = 367), followed by evidence syntheses (n = 211), largely of case reports. There appears a large volume of early preliminary data, as well as a concerted effort to grapple with challenges of researching this topic.
Unsurprisingly, the literature is dominated by studies investigating problems associated with NPS (773/995 records). There is also a growing literature on the prevalence of NPS use, with 130 records presenting survey data internationally. While there were a number of policy discussion papers (n = 84), studies are only beginning to quantitatively evaluate policy interventions (n = 17). There were also a growing number of case reports and reviews discussing the clinical management of NPS, although these were largely focused on managing an emergency.
Type of NPS
The most commonly investigated type of NPS were synthetic cannabinoids (n = 310), followed by synthetic cathinones (n = 271), and then the more generic category of any NPS (n = 259).
We also examined regional variations in studies of NPS type. Synthetic cannabinoids, synthetic cathinones and phenythylamines were most commonly investigated in North America. Research on piperazines was more commonly investigated in Australia or New Zealand. In the UK and the rest of Europe there was more of a focus on generic NPS use.
Evidence gap analysis
We used the findings of the scoping review to identify major gaps in the literature in respect of our a priori research questions, i.e. those that we deemed needed to be addressed from a public health perspective. This exercise enabled us to identify emerging data that were suitable for more detailed narrative syntheses, as presented below.
Use
Although we identified a large number of relevant reports, the evidence base is at an early stage of development. We identified a number of studies on prevalence and patterns of NPS use. Given the UK focus of the research funding we decided to conduct narrative syntheses on UK populations only. We found little data on sociodemographic or other risk factors, other than age or gender, that influence NPS use prevalence.
Problems
The majority of data on problems associated with NPS use were based on case studies or case series of people presenting to emergency departments, and elsewhere with similar acute presentations. This is a large literature (over 300 reports) but given the limitations of these data (i.e. they mainly consisted of case reports) we judged it would be more appropriate to summarize the findings of systematic reviews that synthesize this literature. However, data on long-term regular NPS use and the associated social/health harms (e.g. dependence) have received less research attention. There is almost no epidemiological data on long-term harms but there is a small qualitative literature, 19, 34, 36, [38] [39] [40] [41] [42] from which UK studies were synthesized.
Responses
Data on responses to NPS use and related problems were very limited. We did not find any data specifically investigating the effectiveness of interventions (either specifically developed for NPS users or generic interventions adapted for NPS users) for improving outcomes in NPS users. However, there is an emerging evidence base in policy responses to NPS which we judged warranted further evidence synthesis (Table 1) .
Narrative synthesis UK survey data
We identified 29 studies reporting survey data on NPS use in UK (Table 2) . 9-37 Strongest evidence (from nationally representative samples) was for mephedrone, where the Crime Survey for England and Wales (CSEW) and the Scottish Crime and Justice Survey (SCJS) have been conducting national surveys since 2010-11. Lifetime mephedrone use is uncommon in adults in the general population (~1-2%) but is about two to three times more prevalent in men than women, and also among young adults compared with older adults. Prevalence rates of recent mephedrone use are declining substantially. For example, past year prevalence of mephedrone use declined from 1.3% in 2010-11 to 0.5% in 2014-15 (CSEW, 2015). 13 Nationally representative data on NPS use as a whole and on particular NPS other than mephedrone are less developed. While SCJS have been collecting data on generic NPS use since 2010/2011 specific substances included in this category have changed over time (e.g. mephedrone is no longer considered a 'new drug' in the survey) which makes comparisons of prevalence estimates across years difficult. In addition, CSEW and the All Ireland Prevalence Survey (AIPS) only began collecting data on generic NPS in 2014/2015.
Therefore, considerable uncertainties persist about basic monitoring data. Nationally representative surveys of school children found similar low prevalence for mephedrone use and NPS as a whole. Data on sentinel populations are growing. For example several studies of attendees of gay-friendly night clubs suggest the trend in reduction of mephedrone witnessed nationally may also be occurring in this subgroup too. 24, 26, 37 Qualitative studies of novel psychoactive substance in the UK Qualitative studies of NPS use in the UK 19, 34, 36, [38] [39] [40] [41] [42] are at an early stage of development. Existing studies show potential benefits of collecting qualitative data to inform understanding about long-term effects of NPS use (such as impact on relationships, and risk of violence). In addition, there is potential to further investigate reasons for and patterns of use, and harms. As the evidence base deepens, these data may help to inform targets for behavioural epidemiological studies. Studies assessing aspects of drug market functioning and the effects of mass and social media (including internet forums) have promise to inform future responses including early identification of increases in NPS use or related harms and preventive interventions.
Systematic reviews
Systematic reviews [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] mainly summarized clinical presentation data (Table 3 ) on problems associated with NPS. One review was on all NPS use among people with severe mental illnesses, five on synthetic cannabinoids, two on synthetic cathinones and two on NBOMe.
Most commonly reported side effects of NPS were psychiatric, 45 52 Treatment of these effects appears to mostly involve observation and supportive care, and in severe cases hospitalization. Treatment of intoxication with synthetic opioids was predominantly through opioid antagonists Quantitative studies [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] evaluated effects of legislative prohibitions of NPS use or supply on outcomes including access, e308 JOURNAL OF PUBLIC HEALTH use, healthcare utilization and self-reported exposure and toxicity (Table 4) . Reductions in use, presentations or other outcomes were generally observed, though not always. 58, 67 Studies typically utilized simple counts of routinely collected data, particularly poison centre and hospital admissions data. Study designs were mainly before and after comparisons, which clearly limits attribution of effects as such studies are not designed to address the impact of residual confounding and the regression to the mean phenomenon.
Discussion Summary of principal findings
A comprehensive search of peer-reviewed and grey literature on NPS identified 995 relevant records. We then developed an evidence map and identified evidence gaps based on a priori developed research questions. We identified a number of areas (UK prevalence surveys and qualitative studies, policy evaluation studies and systematic reviews of problems associated with NPS use) where more detailed synthesis were appropriate. However, we judged there was not yet sufficient basis for a full systematic review based on the extensive scoping review and evidence gap analysis. Evidence mapping suggested limited benefits of risk of bias assessments since most studies were unlikely to be of sufficient quality. Study designs, in most cases, were such that it is difficult to establish the nature of relationships between NPS use and problems/harms, or responses to NPS use and outcomes. The more detailed narrative syntheses, taken together with broader evidence mapping, led us to conclude that the literature on NPS is at an early stage of development in its capacity to inform strategic public health responses.
Use
Preliminary findings suggest that NPS use is rare if viewed only in a general population UK context. While it appears that young people, particularly males, are more likely to engage in NPS use there is little other data regarding social or other risk factors. While data on sentinel populations are growing (e.g. attendees of gay-friendly night clubs) 24 ,26,37 the main limitations of these studies regard generalizability of findings across the UK and beyond. 
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Problems
There is now a large literature of case reports and case series reporting acute toxic effects or emergency room attendances related to NPS. The most common side effects reported were psychiatric, cardiovascular, renal and gastrointestinal symptoms. However, due to the limitations of the data it is somewhat challenging to differentiate harms associated with NPS as a whole, and how harms differ between specific types of NPS, both within and between drug classes (such as synthetic cannabinoids, synthetic cathinones, etc.). In addition, data on other harms (e.g. social harms such as impact on relationships, work and family) are currently lacking.
Responses
No data were identified on effectiveness of preventive interventions or interventions for current NPS users. There was limited literature on regulation of NPS which generally showed reductions in incidence, however, limitations in reporting and quality of data limit conclusions that can be drawn from these studies. 58, 67 Examination of the utility of routinely collected NPS data in different settings is needed, incorporating attention to sources of information bias that will facilitate more rigorous assessments of the impacts of major policy changes on NPS use and harms.
Strengths and weaknesses of the current review Strengths
We conducted evidence mapping of a large and diverse literature (995 studies) and constructed an evidence gap analysis to help prioritize topic material for more detailed narrative syntheses. We aimed to minimize error and bias through the use of two researchers to independently select articles and extract data.
Limitations
Scoping reviews are not designed to provide in-depth interrogation of the content of the evidence. Although the scoping review assessed all literature, our narrative syntheses of nationally representative surveys were limited to studies conducted in the UK. It is therefore inappropriate to generalize the prevalence findings beyond the UK. In addition, much of the data on NPS use is self-report and therefore refers to what substance was thought to have been used. However, it is not possible to know with certainty what substance was taken without confirmation with laboratory tests.
A further limitation was that although we identified a large quantity of grey literature, our search methods were weighted to sources in the UK and USA and therefore not necessarily representative of grey literature outside these countries. 
Conclusion
The burden associated with NPS is unclear, as is the shape of any evolving public health responses. These findings suggest directions for research needed to address NPS, though not separately from investigation of other licit and illicit drugs. For further detail on possible priorities for future research indicated by this study, see Mdege et al. 8 ) Although the literature appears large and to have grown quickly, it will need to develop further if it is to inform policy and practice.
Article selection
The screening of titles and abstracts and the selection of articles from retrieved potentially relevant full manuscripts was conducted by two reviewers (N.M. and N.D.M.) using the selection criteria described above. The reviewers independently classified the articles as 'include', 'unclear', or 'exclude', with discrepancies being resolved by discussion or referral to a third reviewer (J.M.). Full manuscripts that did not fulfil all of the criteria were excluded with documented reasons for their exclusion.
Data extraction
Data extraction was performed using EPPI-Reviewer 4 software. The data extraction form was designed by two researchers (N.M. and N.D.M.), piloted on a small selection of articles and adjusted as necessary. The following data was extracted:
• Include/exclude decision, with reasons for exclusion where applicable.
• General characteristics for included studies: author, year, location, setting, study design, publication type.
• Population characteristics: age, gender, ethnicity, sample size, novel psychoactive use status.
• Novel psychoactive substance type:
• Principal focus (use, problems, responses)
• Research recommendations in the case of reviews, systematic reviews, qualitative studies, surveys and articles on responses.
Data from each article were extracted by one researcher and checked by another, with discrepancies being resolved by consensus or recourse to a third researcher if necessary. Where necessary, authors were contacted for missing or unclear data.
Risk of bias (quality) assessment
No risk of bias assessment was conducted. This decision was made after developing the evidence map, for further discussion of this decision see evidence map section below.
Strategy for data synthesis
The framework for data synthesis was the conceptual framework specifically designed for use in data analysis and interpretation for the current scoping review and narrative synthesis, to which the research questions listed above contribute. Data synthesis was done in three stages: evidence mapping, identification of evidence gaps, and then a narrative synthesis of selected research areas.
Evidence map
For reviews addressing complex topic areas, evidence mapping is a well-established tool to explore relevant literature before progressing to more advanced research design decision making. The extracted data was utilized by one researcher to map the literature according to principal focus (use, problems/harms or responses), NPS type, study design, region, setting, year of publication and publication type. This was checked by another researcher. The aim of the map was to provide a comprehensive yet concise descriptive map of the nature and breadth of research on NPS, and identify obvious research gaps.
Identification and evaluation of evidence gaps
After the mapping, an a priori developed set of research questions were then utilized to identify and evaluate evidence gaps, and to make decisions about narrative syntheses. In addition, the conceptual framework guided our evaluation of what was missing from the literature. This process, based on the evidence map, facilitated discussions about categories of evidence where it was feasible to conduct narrative syntheses (in consultation with the project steering group). We initially considered whether it would be possible to restrict the inclusion criteria to a small number of narrowly focused research questions for the purposes of conducting a full systematic review (i.e. including detailed risk of bias assessment).
However, in discussion with the project steering group, we concluded that given the early stage of development for all areas of the literature this would not be the best use of the time and resources of the project. Therefore, we developed broader inclusion criteria that enabled us to conduct narrative syntheses where there was judged to be a sufficient evidence base.
The steering group supported this decision. We were also necessarily pragmatic in our decision-making addressing questions of primary relevance to the UK as the data allowed, in ways which were manageable within the time and resources allocated to the project, bearing in mind the large size of the literature included in the scoping review and the short duration of the project (14 months).
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Narrative synthesis
In addition to the evidence map, and evidence gap analysis, a narrative descriptive synthesis was conducted for the following categories of articles and data:
• Systematic reviews • UK survey data on NPS use • UK-based qualitative studies • Articles on responses, including policy evaluation studies and studies of individual level interventions
